Skip to content
2000
Volume 26, Issue 1
  • ISSN: 1871-5303
  • E-ISSN: 2212-3873
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Introduction

Hyperuricemia Nephropathy (HN) is an emerging metabolic disorder that predisposes individuals to Chronic Kidney Disease (CKD), yet effective treatments remain limited. Inflammation plays a pivotal role in HN-induced kidney injury, with the NLRP3 inflammasome serving as a central mediator of this process. This study investigates the therapeutic effects of Yipishen Xiezhuo Jiedu Decoction (YPSXZJDD), a traditional Chinese medicine, on HN-induced kidney injury through the miR-223/NLRP3/Caspase-1 pathway.

Materials and Methods

The key active components of YPSXZJDD were screened using UHPLC-Q Exactive Orbitrap-MS, and a Protein-Protein Interaction (PPI) network diagram was constructed to explore potential mechanisms of action. The identified components were then utilized to intervene in both cellular and animal models of hyperuricemic nephropathy, evaluating their therapeutic effects and underlying mechanisms.

Results

Catalpol and Tanshinone IIA were identified as the key active components of YPSXZJDD. These compounds significantly mitigated renal epithelial cell apoptosis and inflammation by upregulating miR-223, which in turn inhibited the NLRP3/Caspase-1 pathway. The upregulation of miR-223 led to a marked reduction in NLRP3 activity and inflammatory responses, thereby alleviating HN-induced kidney damage.

Discussion

The findings of this study underscore the critical role of miR-223 in regulating the NLRP3 inflammasome and highlight its potential as a therapeutic target for HN. The inhibition of the NLRP3/Caspase-1 pathway by miR-223 significantly reduces inflammation and renal injury, demonstrating the therapeutic efficacy of YPSXZJDD. These results offer a novel perspective on the application of traditional Chinese medicine in treating HN, highlighting the importance of miR-223 in regulating inflammation.

Conclusion

This study demonstrates that YPSXZJDD alleviates HN-induced kidney injury by upregulating miR-223 and inhibiting the NLRP3/Caspase-1 pathway. The therapeutic potential of YPSXZJDD is supported by its ability to mitigate inflammation and renal damage, offering a promising approach for HN treatment. Further research into the broader role of miR-223 in kidney disease and related conditions is warranted to expand the understanding of its therapeutic applications.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/emiddt/10.2174/0118715303402744250704071034
2025-07-10
2025-12-15

  • From This Site

    /content/journals/emiddt/10.2174/0118715303402744250704071034
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/emiddt/26/1/EMIDDT-26-E18715303402744.html?itemId=/content/journals/emiddt/10.2174/0118715303402744250704071034&mimeType=html&fmt=ahah

References

  1. SrivastavaA. KazeA.D. McMullanC.J. IsakovaT. WaikarS.S. Uric acid and the risks of kidney failure and death in individuals with CKD.Am. J. Kidney Dis.201871336237010.1053/j.ajkd.2017.08.01729132945
     [Google Scholar]
  2. RenQ. WangB. GuoF. HuangR. TanZ. MaL. FuP. Natural flavonoid pectolinarigenin alleviated hyperuricemic nephropathy via suppressing TGFβ/SMAD3 and JAK2/STAT3 signaling pathways.Front. Pharmacol.20221279213910.3389/fphar.2021.79213935153751
     [Google Scholar]
  3. LiL. ZhangY. ZengC. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia.Am. J. Transl. Res.20201273167318132774692
     [Google Scholar]
  4. YanaiH. AdachiH. HakoshimaM. KatsuyamaH. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease.Int. J. Mol. Sci.20212217922110.3390/ijms2217922134502127
     [Google Scholar]
  5. JohnsonR.J. Sanchez LozadaL.G. LanaspaM.A. PianiF. BorghiC. Uric acid and chronic kidney disease: Still more to do.Kidney Int. Rep.20238222923910.1016/j.ekir.2022.11.01636815099
     [Google Scholar]
  6. YangL. WangB. MaL. FuP. Traditional chinese herbs and natural products in hyperuricemia-induced chronic kidney disease.Front. Pharmacol.20221397103210.3389/fphar.2022.97103236016570
     [Google Scholar]
  7. ShuiG. CaiZ. WangF. ChenT. HuangX. CaiY. MiX. Simiao pill inhibits epithelial mesenchymal transition in a mouse model of chronic hyperuricemic nephropathy by inhibiting NLRP3 inflammasome activation.BMC Complement. Med. Ther.202222127810.1186/s12906‑022‑03757‑036271349
     [Google Scholar]
  8. TangG. LiS. ZhangC. ChenH. WangN. FengY. Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.Acta Pharm. Sin. B20211192749276710.1016/j.apsb.2020.12.02034589395
     [Google Scholar]
  9. MaH. GuoX. CuiS. WuY. ZhangY. ShenX. XieC. LiJ. Dephosphorylation of AMP-activated protein kinase exacerbates ischemia/reperfusion-induced acute kidney injury via mitochondrial dysfunction.Kidney Int.2022101231533010.1016/j.kint.2021.10.02834774556
     [Google Scholar]
  10. NieW. ZhuH. SunX. ZhouJ. XuH. YuZ. LuM. JiangB. ZhouL. ZhouX. Catalpol attenuates hepatic glucose metabolism disorder and oxidative stress in triptolide-induced liver injury by regulating the SIRT1/HIF-1α pathway.Int. J. Biol. Sci.202420104077409710.7150/ijbs.9736239113710
     [Google Scholar]
  11. LiuJ. LiuS. YuM. LiJ. XieZ. GaoB. LiuY. Anti-inflammatory effect and mechanism of catalpol in various inflammatory diseases.Drug Dev. Res.20238471376139410.1002/ddr.2209637534768
     [Google Scholar]
  12. LuT.C. WuY.H. ChenW.Y. HungY.C. Targeting oxidative stress and endothelial dysfunction using tanshinone iia for the treatment of tissue inflammation and fibrosis.Oxid. Med. Cell. Longev.202220221281178910.1155/2022/281178935432718
     [Google Scholar]
  13. BohatáJ. HorváthováV. PavlíkováM. StibůrkováB. Circulating microRNA alternations in primary hyperuricemia and gout.Arthritis Res. Ther.202123118610.1186/s13075‑021‑02569‑w34246297
     [Google Scholar]
  14. WangS. LiuW. WeiB. WangA. WangY. WangW. GaoJ. JinY. LuH. KaY. YueQ. Traditional herbal medicine: Therapeutic potential in acute gouty arthritis.J. Ethnopharmacol.202433011818210.1016/j.jep.2024.11818238621464
     [Google Scholar]
  15. LuoZ. YangF. HongS. WangJ. ChenB. LiL. YangJ. YaoY. YangC. HuY. WangS. XuT. WuJ. Role of microRNA alternation in the pathogenesis of gouty arthritis.Front. Endocrinol.20221396776910.3389/fendo.2022.96776936034424
     [Google Scholar]
  16. LiS. SunY. SongM. SongY. FangY. ZhangQ. LiX. SongN. DingJ. LuM. HuG. NLRP3/caspase-1/GSDMD–mediated pyroptosis exerts a crucial role in astrocyte pathological injury in mouse model of depression.JCI Insight202162314685210.1172/jci.insight.14685234877938
     [Google Scholar]
  17. TianJ. ZhouD. XiangL. LiuX. ZhangH. WangB. XieB. MiR-223-3p inhibits inflammation and pyroptosis in monosodium urate-induced rats and fibroblast-like synoviocytes by targeting NLRP3.Clin. Exp. Immunol.2021204339641010.1111/cei.1358733608866
     [Google Scholar]
  18. HuangX. MaY. WangZ. WangW. WenC. WangX. ZhangM. Determination of ketamine and palmatine in rat plasma by UHPLC-MS/MS and their pharmacokinetic interaction.Curr. Pharm. Anal.202420322422910.2174/0115734129304769240403075839
     [Google Scholar]
  19. WangS. CuiX. HuiR. YaoW. ZhaoB. LiJ. MiaoJ. Grp94 inhibitor HCP1 suppressed the replication of SVA in BHK-21 Cells and PK-15 cells.Curr. Mol. Pharmacol.202417105072321841337876268
     [Google Scholar]
  20. NiJ. ShangY. WangW.D. WangC. WangA.M. LiG.J. ChenS.Z. FASN inhibitors enhance bestatin-related tumor cell apoptosis through upregulating PEPT1.Curr. Mol. Pharmacol.202316777178636411574
     [Google Scholar]
  21. ZhangH. PengX. WuX. WuG. PengC. HuangB. HuangM. DingJ. MaoC. MiR-129-2-3p inhibits esophageal carcinoma cell proliferation, migration, and invasion via targeting DNMT3B.Curr. Mol. Pharmacol.202316111612310.2174/187446721566622030812271635260066
     [Google Scholar]
  22. HuangY. SunW. ZhuD. LiuL. FengJ. YiQ. RBM3 inhibits the cell cycle of cutaneous squamous cell carcinoma through the PI3K/AKT signaling pathway.Curr. Mol. Pharmacol.2024171876142932376010.2174/011876142932376024071205000639041256
     [Google Scholar]
  23. ZhangM. ZhuX. WuJ. HuangZ. ZhaoZ. ZhangX. XueY. WanW. LiC. ZhangW. WangL. ZhouM. ZouH. WangL. Prevalence of hyperuricemia among chinese adults: Findings from two nationally representative cross-sectional surveys in 2015–16 and 2018–19.Front. Immunol.20221279198310.3389/fimmu.2021.79198335197964
     [Google Scholar]
  24. ZhouJ. WangC. ZhangX. WuZ. WuY. LiD. GaoJ. Shizhifang ameliorates pyroptosis of renal tubular epithelial cells in hyperuricemia through inhibiting NLRP3 inflammasome.J. Ethnopharmacol.202331711677710.1016/j.jep.2023.11677737311502
     [Google Scholar]
  25. CuiD. LiuS. TangM. LuY. ZhaoM. MaoR. WangC. YuanY. LiL. ChenY. ChengJ. LuY. LiuJ. Phloretin ameliorates hyperuricemia-induced chronic renal dysfunction through inhibiting NLRP3 inflammasome and uric acid reabsorption.Phytomedicine20206615311110.1016/j.phymed.2019.15311131790902
     [Google Scholar]
  26. YangS. LiuH. FangX.M. YanF. ZhangY. Signaling pathways in uric acid homeostasis and gout: From pathogenesis to therapeutic interventions.Int. Immunopharmacol.202413211193210.1016/j.intimp.2024.11193238560961
     [Google Scholar]
  27. OuZ. ZhaoM. XuY. WuY. QinL. FangL. XuH. ChenJ. Huangqi guizhi wuwu decoction promotes m2 microglia polarization and synaptic plasticity via sirt1/NF-κB/NLRP3 pathway in MCAO rats.Aging20231519100311005610.18632/aging.20498937650573
     [Google Scholar]
  28. LiuX. GaoL. HuangX. DengR. WuS. PengY. LuJ. Huangqi-Danshen decoction protects against cisplatin-induced acute kidney injury in mice.Front. Pharmacol.202314123682010.3389/fphar.2023.123682038034992
     [Google Scholar]
  29. HuangX. GaoL. DengR. PengY. WuS. LuJ. LiuX. Huangqi-Danshen decoction reshapes renal glucose metabolism profiles that delays chronic kidney disease progression.Biomed. Pharmacother.202316411498910.1016/j.biopha.2023.11498937315436
     [Google Scholar]
  30. WuZ.M. LuoJ. ShiX.D. ZhangS.X. ZhuX.B. GuoJ. Icariin alleviates rheumatoid arthritis via regulating miR-223-3p/NLRP3 signalling axis.Autoimmunity202053845045810.1080/08916934.2020.183648833084415
     [Google Scholar]
/content/journals/emiddt/10.2174/0118715303402744250704071034
Loading
Yipishen Xiezhuo Jiedu Decoction in Ameliorating Kidney Damage Through miR-223/NLRP3/Caspase-1 Pathway
Endocr Metab Immune Disord Drug Targets 26, E18715303402744 (2026); https://doi.org/10.2174/0118715303402744250704071034
/content/journals/emiddt/10.2174/0118715303402744250704071034
/content/journals/emiddt/10.2174/0118715303402744250704071034
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): Hyperuricemic nephropathy; inflammation; kidney disease; miR-223; NLRP3; YPSXZJDD

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test